We are live on ! Find out more
SLNO icon

Soleno Therapeutics

Delisted

SLNO was delisted on the 15th of May, 2026.

0 hedge funds and large institutions have $0 invested in Soleno Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 229 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 231 → 0 (-231)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $1.85B

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 229

120.8% less ownership

Funds ownership: 120.8% → 0% (-121%)

Holders
–
Holders Change
-231
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
229
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SLNO Hedge Fund Activity: Q2 2026 in Review

0 of the 8,401 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q2 2026, worth a combined $0 — down 100% from $2.09B a quarter earlier.

Sellers outnumbered buyers: 229 funds closed out of SLNO and 0 opened new positions — a net loss of 229 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Fidelity Investments, exiting entirely with an estimated $194M sold.

  • 0 institutional investors held Soleno Therapeutics (SLNO) as of Q2 2026, down from 231 in Q1 2026.
  • Funds reported $0 of Soleno Therapeutics stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Soleno Therapeutics positions in Q2 2026 and 229 closed out, a net change of -229 holders.
  • The largest Soleno Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $194M sold.

Based on aggregated 13F filings for Q2 2026.